Treatment of early-stage breast cancer with percutaneous thermal ablation, an open-label randomised phase 2 screening trial: rationale and design of the THERMAC trial

INTRODUCTION: Breast cancer is the most frequently diagnosed malignancy worldwide but almost half of the patients have an excellent prognosis with a 5-year survival rate of 98%–99%. These patients could potentially be treated with thermal ablation to avoid surgical excision, reduce treatment-related...

Descripción completa

Detalles Bibliográficos
Autores principales: van de Voort, Elles M F, Struik, Gerson M, Koppert, Linetta B, Moelker, Adriaan, Debets, Reno, Yo, Glenn, Macco, Maura J P V, Sinke, Renata H J A, Franckena, Martine, Birnie, Erwin, Verhoef, Cornelis, Klem, Taco M A L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8422491/
https://www.ncbi.nlm.nih.gov/pubmed/34489297
http://dx.doi.org/10.1136/bmjopen-2021-052992

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8422491/
https://www.ncbi.nlm.nih.gov/pubmed/34489297
http://dx.doi.org/10.1136/bmjopen-2021-052992

Ejemplares similares